---
url: https://www.servicesaustralia.gov.au/rheumatoid-arthritis-toxicity-and-severity-descriptors
title: Rheumatoid arthritis toxicity and severity descriptors - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:43:56.609Z
source: servicesaustralia.gov.au
---
# Rheumatoid arthritis toxicity and severity descriptors

Toxicity and severity descriptors for treatments required to be trialled before accessing PBS-subsidised biological medicines to treat rheumatoid arthritis.

## on this page

-   [Azathioprine](#a1)
-   [Cyclosporin](#a2)
-   [Hydroxychloroquine](#a3)
-   [Leflunomide](#a4)
-   [Methotrexate](#a5)
-   [Sulfasalazine](#a6)

ALT - alanine aminotransferase  
AST - aspartate aminotransferase  
BP - blood pressure  
ECG - electrocardiogram  
IV - intravenous  
NIH - National Institutes of Health  
ULN - upper limit of normal  
WCC - white cell count

## Azathioprine

Only valid for adult patients. Azathioprine must be at a dose of at least 1 mg per kg per day.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools per day over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN or ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Ç Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Neurology or senses**

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

**Pulmonary**

Pneumonitis or pulmonary infiltrates

Radiographic changes, respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

Fatigue, malaise

Severe, loss of ability to perform some activities

3 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39 °C (oral or tympanic)

2 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Secondary malignancy

Secondary malignancy present

4

## Cyclosporin

Only valid for adult patients. Cyclosporin must be at a dose of at least 2 mg per kg per day.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Cardiovascular**

Hypertension

Recurrent or persistent rise of > 20 mmHg diastolic BP or rise to > 150 over 90 on 2 occasions if BP previously normal

2 (or higher)

Fluid retention

Symptomatic, limiting function, unresponsive to therapy or requiring drug discontinuation

3 (or higher)

**Dermatology or skin**

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools perday over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

Weight gain or loss

20% or more weight gain or loss

3 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN **or** ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Musculoskeletal**

Muscle weakness

Symptomatic and interfering with function

2 (or higher)

**Neurology or senses**

Ataxia (incoordination)

Mild symptoms interfering with function but not interfering with activities of daily living

2 (or higher)

Decreased level of consciousness

Somnolence or sedation interfering with function but not interfering with activities of daily living

2 (or higher)

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Neuropathy - sensory

Objective sensory loss or paraesthesia interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

**Renal**

Haematuria

Macroscopic (or dipstick +++) confirmed on 2 separate occasions

2 (or higher)

Proteinuria

\> 1.0 g per 24 hours, elevated urine protein-creatinine ratios, (dipstick protein ++ or greater), confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine > 1.5 ULN or creatinine clearance < 30 mL per min

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

Fatigue, malaise

Severe, loss of ability to perform some activities

3 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39 °C (oral or tympanic)

2 (or higher)

Hyperkalaemia

Potassium > 6 mmol per L

3 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Secondary malignancy

Secondary malignancy present

4

## Hydroxychloroquine

Only valid for adult patients. Hydroxychloroquine must be at a dose of at least 200 mg daily.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools perday over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN or ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Musculoskeletal**

Muscle weakness

Symptomatic and interfering with function

2 (or higher)

**Neurology or senses**

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Neuropathy - motor

Objective weakness interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

Vision - cornea or retina

Symptomatic corneal or retinal changes present

1 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

## Leflunomide

Only valid for adult patients. Leflunomide must be at a dose of at least 10 mg daily.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Cardiovascular**

Arrhythmia

Symptomatic and requiring therapy

3 (or higher)

Hypertension

Recurrent or persistent rise of > 20 mmHg diastolic BP or rise to > 150 over 90 on 2 occasions if BP previously normal

2 (or higher)

Fluid retention

Symptomatic, limiting function, unresponsive to therapy or requiring drug discontinuation

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools perday over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Weight gain or loss

20% or more weight gain or loss

3 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN or ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Neurology or senses**

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

**Pulmonary**

Cough (severe)

Severe cough or coughing spasm, poor control or unresponsive to treatment. Evidence of reversal on cessation of treatment

3 (or higher)

Pneumonitis or pulmonary infiltrates

Radiographic changes, respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary fibrosis

Respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary symptoms - new or worsening (probable drug-induced pneumonitis)

Development of syndrome consistent with drug-induced pneumonitis (for example, cough, dyspnoea, fever, hypoxaemia) with lung infiltrates on imaging (refer Searles McKendry criteria)

Refer Searles McKendry criteria

**Renal**

Haematuria

Macroscopic (or dipstick +++) confirmed on 2 separate occasions

2 (or higher)

Proteinuria

\> 1.0 g per 24 hours, elevated urine protein-creatinine ratios, (dipstick protein ++ or greater), confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine > 1.5 ULN or creatinine clearance < 30 mL permin

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

Fatigue, malaise

Severe, loss of ability to perform some activities

3 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39 °C (oral or tympanic)

2 (or higher)

Hypokalaemia

Potassium < 3 mmol per L

3 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Secondary malignancy

Secondary malignancy present

4

## Methotrexate

Only valid for adult patients. Methotrexate must be at a dose of at least 20 mg weekly.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Cardiovascular**

Pericardial effusion or pericarditis

Pericarditis (pericardial rub, ECG changes or chest pain)

2 (or higher)

Thrombosis or embolism

Requiring anticoagulant therapy

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools perday over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased, and symptoms don't improve with at least 2 of the following measures:

1.  reduction of the methotrexate dose
2.  folinic acid or folic acid supplementation
3.  switching from oral to intramuscular dosing
4.  dividing the methotrexate dose over 12 hours

A minimum of 3 doses of methotrexate should have been trialled

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN or ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Musculoskeletal**

Osteonecrosis  
(avascular necrosis)

Symptomatic and interfering with function

2 (or higher)

Osteoporosis

Symptomatic and requiring treatment

3 (or higher)

**Neurology or senses**

Decreased level of consciousness

Somnolence or sedation interfering with function but not interfering with activities of daily living

2 (or higher)

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

**Pulmonary**

Cough (severe)

Severe cough or coughing spasm, poor control or unresponsive to treatment. Evidence of reversal on cessation of treatment.

3 (or higher)

Pneumonitis or pulmonary infiltrates

Radiographic changes, respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary fibrosis

Respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary symptoms - new or worsening (probable drug-induced pneumonitis)

Development of syndrome consistent with drug-induced pneumonitis (for example, cough, dyspnoea, fever, hypoxaemia) with lung infiltrates on imaging  
(refer Searles McKendry criteria)

 

**Renal**

Haematuria

Macroscopic (or dipstick +++) confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine > 1.5 ULN or creatinine clearance < 30 mL per min

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

Fatigue, malaise

Severe, loss of ability to perform some activities

3 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39 °C (oral or tympanic)

2 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Nodulosis (following introduction of methotrexate therapy)

Development of multiple new nodules causing significant local pressure symptoms and distress to patient

 

Secondary malignancy

Secondary malignancy present

4

## Sulfasalazine

Only valid for adult patients. Sulfasalazine must be at a dose of at least 2 g daily.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools per day over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pretreatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN or ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Neurology or senses**

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Neuropathy - sensory

Objective sensory loss or paraesthesia interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

**Pulmonary**

Cough (severe)

Severe cough or coughing spasm, poor control or unresponsive to treatment. Evidence of reversal on cessation of treatment

3 (or higher)

Pneumonitis or pulmonary infiltrates

Radiographic changes, respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary fibrosis

Respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

**Renal**

Haematuria

Macroscopic (or dipstick +++) confirmed on 2 separate occasions

2 (or higher)

Proteinuria

\> 1.0 g per 24 hours, elevated urine protein-creatinine ratios, (dipstick protein ++ or greater), confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine > 1.5 ULN or creatinine clearance < 30 mL per min

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39 °C (oral or tympanic)

2 (or higher)
